Jensen L H, Petersen E N, Braestrup C, Honoré T, Kehr W, Stephens D N, Schneider H, Seidelmann D, Schmiechen R
Psychopharmacology (Berl). 1984;83(3):249-56. doi: 10.1007/BF00464789.
We describe here biochemical and pharmacological effects of the beta-carboline ZK 93426 was compared with Ro 15-1788 and CGS 8216, two compounds previously described as BZ receptor antagonists. Certain effects of ZK 93426, Ro 15-1788 and CGS 8216 were quite similar (e.g., 3H-FNM displacement, "GABA ratio", "photo-shift"). In most pharmacological tests ZK 93426 and Ro 15-1788 lacked overt effects; Ro 15-1788 was a weak agonist in some paradigms, while ZK 93426 exhibited a potent proconflict effect but also a weak anticonvulsant effect. This interesting finding with ZK 93426 suggests that BZ receptor ligands may possess differential efficacy at BZ receptor subtypes. In contrast, CGS 8216 exhibited potent proconvulsant effects in several paradigms in addition to proconflict and pentylenetetrazol generalizing effects. ZK 93426, Ro 15-1788 and CGS 8216 were almost equally potent as antagonists of the effects of BZ receptor agonists, such as diazepam and lorazepam. However, ZK 93426 was the most potent inhibitor of the convulsions produced by the BZ receptor inverse agonist DMCM.
我们在此描述了β-咔啉ZK 93426的生化和药理作用,并将其与Ro 15-1788和CGS 8216进行了比较,后两种化合物先前被描述为苯二氮䓬(BZ)受体拮抗剂。ZK 93426、Ro 15-1788和CGS 8216的某些作用相当相似(例如,3H-FNM置换、“GABA比率”、“光移位”)。在大多数药理试验中,ZK 93426和Ro 15-1788没有明显作用;Ro 15-1788在某些实验范式中是一种弱激动剂,而ZK 93426表现出强效的冲突促进作用,但也有弱的抗惊厥作用。ZK 93426的这一有趣发现表明,BZ受体配体在BZ受体亚型上可能具有不同的效能。相比之下,CGS 8216除了具有冲突促进作用和戊四氮泛化作用外,在几种实验范式中还表现出强效的惊厥作用。ZK 93426、Ro 15-1788和CGS 8216作为BZ受体激动剂(如地西泮和劳拉西泮)作用的拮抗剂,效力几乎相同。然而,ZK 93426是BZ受体反向激动剂DMCM产生惊厥作用的最有效抑制剂。